AI as an additional tool allows for the detection of abnormalities at an early stage.

A trial is underway at Aberdeen Royal Infirmary to investigate the use of artificial intelligence (AI) in assisting radiologists with the review of mammograms. Mammograms are low-level X-rays used in breast cancer screenings to detect changes too small to see or feel. The trial has already proven successful in identifying early-stage breast cancer for one participant, who will now undergo surgery.

The number of radiologists available to review mammogram results is decreasing, despite an increasing number of women attending routine breast screenings in Scotland. AI, which allows computers to perform tasks that typically require human intelligence, is already being used across various industries. In healthcare, AI is seen as a powerful tool to enhance the speed of drug and disease discovery, rather than replace healthcare practitioners. (BBC)

In Scotland, the number of screen-detected breast cancers has increased, leading to a greater workload for radiologists. The NHS Grampian’s Gemini project, a collaboration between the NHS, the University of Aberdeen, and private industry, is utilizing an AI model called Mia, developed by Kheiron Medical Technologies, with support from Microsoft’s cloud computing services. Due to current rules set by the National Screening Council, AI cannot be automatically deployed in screenings. Therefore, the AI model is being trialed as an additional check at the end of mammogram scan reviews.

During the trial, radiologists can use the AI software to identify differences between two mammogram scans, focusing on areas of concern. This additional tool allows for the detection of abnormalities at an early stage. Participants in the trial have expressed that the use of AI made the process feel less intrusive compared to having another human review their scans.

Scotland’s breast screening program has faced challenges due to staff shortages, with a significant number of radiology staff nearing retirement age. The potential of AI to cover a portion of the screening image reading burden has been highlighted, but the goal of the evaluation is to determine the best way to integrate AI into the workflow, whether it is replacing a radiologist, assisting in reading mammograms, or improving cancer detection as a safety net.

The success of the Aberdeen trial has led to plans for more than 30 NHS trusts across the UK to utilize the AI technology, benefiting millions of patients. In England, trusts are also exploring how AI can support better and faster outcomes for breast cancer patients.

AI continues to play a significant role in healthcare, helping doctors save lives by improving efficiency and accuracy in diagnosis and treatment.

Related Story:  Artera Announces $90M Funding For Its AI-Driven Prostate Test